DT&CRO (CEO Chaekyu Park) announced on August 22, 2025 that it has signed a strategic Memorandum of Understanding (MOU) with RudaCure (CEO Yongho Kim), a 生物科技公司 specializing in 创新药物 研发.
This agreement aims to respond to the increasingly sophisticated demand for 药物开发 in the 国内外 制药 and bio industries, combining the expertise and strengths of both companies to achieve innovative 研发 outcomes and 全球竞争力.
The importance of strategic collaboration to enhance the efficiency of 临床前 and 临床试验 and accelerate 药物开发 is growing, and this agreement was planned within this industry trend.
Through this agreement, both companies will closely collaborate in various areas including: ▲discovery and 研发 cooperation for 创新药物候选物s, ▲临床前 and 临床试验 planning and execution cooperation, and ▲establishment of data-based analysis and research support systems.
DT&CRO, as a specialized CRO (合同研究组织), possesses accumulated experience in 临床前 and 临床试验 planning and execution, as well as regulatory response capabilities. RudaCure's innovative 药物开发 管线 (including 干眼症治疗药 RCI001 and 疼痛治疗药 RCI002) and platform technology can achieve synergy effects when combined with DT&CRO's clinical development infrastructure and operational expertise.
CEO Park of DT&CRO stated, "This MOU with RudaCure is expected to create significant synergies in the 临床前 and 临床试验 fields. Through combining both companies' technologies and know-how, we will contribute to the domestic 生物制药 industry's leap to the next level."
CEO Kim of RudaCure stated, "Through collaboration with DT&CRO's professional CRO experience and capabilities, we expect to more effectively advance the development of our new drugs including RCI001 and RCI002. We will work together to achieve tangible research outcomes."
